Skip to content
Homepage
Author:
Telomir Pharmaceuticals, Inc
Posted Date:
June 15, 2026
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
Telomir Pharmaceuticals, Inc
June 15, 2026
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease
Telomir Pharmaceuticals, Inc
May 20, 2026
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
Telomir Pharmaceuticals, Inc
April 30, 2026
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
Telomir Pharmaceuticals, Inc
April 24, 2026
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
Telomir Pharmaceuticals, Inc
March 31, 2026
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
Telomir Pharmaceuticals, Inc
February 17, 2026
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
Telomir Pharmaceuticals, Inc
February 14, 2026
